Phase I study of docetaxel and epirubicin in advanced breast cancer

被引：0
|
作者：
Panagos, G [1 ]
Mavroudis, D [1 ]
Potamianou, A [1 ]
Malamos, N [1 ]
Kourousis, C [1 ]
Kakolyris, S [1 ]
Souglakos, J [1 ]
Sarra, E [1 ]
Giannakakis, T [1 ]
Georgoulias, V [1 ]
机构：
[1] Univ Gen Hosp, Dept Med Oncol, Greek Cooperat Grp Breast Canc, Heraklion 71110, Crete, Greece
来源：
ANNALS OF ONCOLOGY | 1998年 / 9卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
97P
引用
收藏
页码：21 / 21
页数：1
相关论文
共 50 条
  • [31] Gemcitabine plus dose-escalated epirubicin in advanced breast cancer: results of a phase I study
    Diana Lüftner
    Bernd Flath
    Costa Akrivakis
    Hans-Günther Mergenthaler
    Ute Ohnmacht
    Michael Arning
    Kurt Possinger
    [J]. Investigational New Drugs, 1998, 16 : 141 - 146
  • [32] Phase I/II pharmacokinetic study of pemetrexed and epirubicin in patients with locally advanced or metastatic breast cancer
    Paridaens, Robert
    Dirix, Luc
    Dumez, Herlinde
    Prove, Annemie
    Wildiers, Hans
    Alvarez, Ana
    Oliveira, Celia Tosello
    Latz, Jane
    Simms, Lorinda
    Melemed, Allen
    [J]. CLINICAL BREAST CANCER, 2007, 7 (11) : 861 - 866
  • [33] Capecitabine in association with epirubicin and docetaxel as a first line treatment in advanced breast cancer. A multicenter phase II study.
    Rosso, R
    Del Mastro, L
    Durando, A
    Garrone, O
    Cherubini, R
    Scotto, T
    Genta, F
    Occelli, M
    Bellino, R
    Bighin, C
    Catzeddu, T
    Stevani, I
    Baldini, A
    Lambiase, A
    Venturini, M
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2001, 69 (03) : 270 - 270
  • [34] Epirubicin/cyclophosphamide followed by docetaxel as the primary systemic therapy for locally advanced breast cancer: The final analysis of a phase II study
    Hirano, Akira
    Kamimura, Mari
    Ogura, Kaoru
    Hattori, Akinori
    Okubo, Fumie
    Inoue, Hiroaki
    Kinoshita, Jun
    Fujibayashi, Mariko
    Shimizu, Tadao
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [35] Docetaxel and epirubicin compared with docetaxel and prednisone in advanced castrate-resistant prostate cancer: a randomised phase II study
    R Petrioli
    A Pascucci
    R Conca
    G Chiriacò
    E Francini
    G Bargagli
    A I Fiaschi
    A Manganelli
    G De Rubertis
    G Barbanti
    R Ponchietti
    G Francini
    [J]. British Journal of Cancer, 2011, 104 : 613 - 619
  • [36] Docetaxel and epirubicin compared with docetaxel and prednisone in advanced castrate-resistant prostate cancer: a randomised phase II study
    Petrioli, R.
    Pascucci, A.
    Conca, R.
    Chiriaco, G.
    Francini, E.
    Bargagli, G.
    Fiaschi, A. I.
    Manganelli, A.
    De Rubertis, G.
    Barbanti, G.
    Ponchietti, R.
    Francini, G.
    [J]. BRITISH JOURNAL OF CANCER, 2011, 104 (04) : 613 - 619
  • [37] Docetaxel and epirubicin as neoadjuvant chemotherapy (CT) in locally advanced breast cancer (LABC).
    Alkhatib, F
    Alawadi, S
    Grohn, P
    Motawy, M
    Fayaz, S
    Patel, J
    Attia, N
    Trad, D
    Delvadia, M
    [J]. ANNALS OF ONCOLOGY, 2000, 11 : 21 - 22
  • [38] Phase I trial of pegylated liposomal doxorubicin and docetaxel in advanced breast cancer
    Sparano, JA
    Malik, U
    Rajdev, L
    Sarta, C
    Hopkins, U
    Wolff, AC
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (12) : 3117 - 3125
  • [39] Phase II study of weekly epirubicin and docetaxel as first line chemotherapy in metastatic breast cancer
    Gamucci, Teresa
    D'Ottavio, Anna Maria
    Gareri, Roberta
    Vaccaro, Angela
    Belli, Franca
    Nunziata, Corrado
    Meliffi, Loretta
    Moscetti, Luca
    Barduagni, Mario
    Sperduti, Isabella
    [J]. ANNALS OF ONCOLOGY, 2004, 15 : 48 - 49
  • [40] Gemcitabine, epirubicin and docetaxel as primary systemic therapy in patients with early breast cancer: results of a multicentre phase I/II study
    Schneeweiss, A
    Huober, J
    Sinn, HP
    von Fournier, D
    Rudlowski, C
    Beldermann, F
    Krauss, K
    Solomayer, E
    Hamerla, R
    Wallwiener, D
    Bastert, G
    [J]. EUROPEAN JOURNAL OF CANCER, 2004, 40 (16) : 2432 - 2438
12345